Drugs / Serp-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00243308 | Oct 2005 → Jul 2008 | coronary atherosclerosis, coronary restenosis, intermediate coronary syndrome | Viron Therapeutics Inc | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Serp-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00243308 ↗ |
| Known as | Serine proteinase-1 | “Serine proteinase-1 (Serp-1)” NCT00243308 ↗ |
| Modality | Protein / enzyme biologic | “A myxoma virus-derived serpin Serp-1” PMID 21062996 ↗ Nov 2010 |
| Route | Intravenous | “Serp-1 by intravenous (IV) bolus injection daily for 3 days” NCT00243308 ↗ |